by Madaline Spencer | Aug 23, 2024
Richard Wasserman, MD, PhD, Medical Director of Pediatric Allergy and Immunology at Medical City Children’s Hospital, discusses the FDA expanded label approval for Xembify (immune globulin subcutaneous human-klhw) for primary immunodeficiencies (PIDs). ...
by Madaline Spencer | Aug 22, 2024
Ponni Subbiah, MD, Senior Vice President of Acadia, Global Head of Medical Affairs and Chief Medical Officer, discusses long-term data from clinical trial extension of trofinetide in patients with Rett syndrome. Rett syndrome is a neurodevelopmental...
by Madaline Spencer | Aug 21, 2024
Dana Rizk, MD, Professor of Medicine at the University of Alabama at Birmingham, discusses the U.S. Food and Drug Administration (FDA) accelerated approval of Fabhalta (iptacopan) for the reduction of proteinuria in adults with IgA nephropathy (IgAN). ...
by Madaline Spencer | Aug 20, 2024
Stephen Russell, MD, Professor of Ophthalmology and Visual Sciences and Dina J. Schrage Professor of Macular Degeneration Research at the University of Iowa Carver College of Medicine, discusses long-term data on Luxturna (voretigene neparvovec-rzyl) for retinal...
by Madaline Spencer | Aug 16, 2024
Alan Percy, MD, Professor of Pediatrics, Neurology, Neurobiology, Genetics, and Psychology at University of Alabama, Birmingham and lead author for the LILAC-1 and LILAC-2 studies, discusses long-term data from clinical trial extension of trofinetide in patients with...
